Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
InvestorsHub on MSN
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene ...
Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果